Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin

for Health Care Providers

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin plus or minus Protease Inhibitor (Boceprevir or Telaprevir)

Back to Tables

Week

*Intervals may need to be increased based on patient tolerance and response to treatment in patients with significant declines in blood counts, renal insufficiency, diabetes, cirrhosis or other indications.

**Recommended for all patients at baseline and periodically during antiviral treatment in patients with diabetes, hypertension or as needed for visual complaints.

Necessary02481224Every 4-weeks ThereafterEnd-of-Treatment24 weeks Post-treatment
HCV RNA Follow Algorithm for additional timepoints
CBC with differential√*
Liver function tests√*
Psychiatric/Substance Use Screening√*
Renal panel *
Glucose *
TSH *
Uric acid (if on telaprevir)*
Pregnancy test
Recommended
Fundoscopic Exam**
Urine Toxicology Screen